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Introduction
Aspergillus spp., Candida spp., and Cryptococcus spp. are opportunistic human pathogens that together account for most global invasive fungal infections. Considered a significant and growing challenge to human health 1, 2 , infections attributable to Aspergillus fumigatus are a significant cause of morbidity and mortality in an ever-expanding group of patients. For patients undergoing haematopoietic stem cell transplantation (HSCT) and in particular allogeneic grafts, invasive aspergillosis (IA) is an important cause of pulmonary related mortality 3 . Chronic and allergic forms are rarely life threatening, however, they are estimated to have global burdens of approximately 1.2 million and 4.8 million people respectively 4, 5 . Moreover, they may affect patients with an intact immune system but have other medical co-morbidities placing them at a higher risk of fungal sensitisation and subsequent allergic disease. A recent phenomenon in both immunosuppressed and immunocompetent individuals is post influenza aspergillosis in the Intensive Care Unit (ICU) 6 .
As both fungi and mammals are eukaryotes, antifungal drug development faces the fundamental challenge of selective toxicity. Structures that are unique to fungi or that bear exploitable dissimilarities, such as the cell membrane and the cell wall, are exploited by the polyenes 7 , azoles 8 and echinocandins 9 respectively. Together with flucytosine 10 , they represent the only antifungal classes clinically licensed for the prevention and treatment of aspergillosis 3 and offer limited degrees of efficaciousness through a restricted spectrum of cellular targets, poor clinical and physicochemical properties and rising rates of drug resistance 11 particularly exacerbated through extensive agricultural over-use of antifungal azoles 2, 12 . A lack of innovation, investment and infrastructure in pharmaceutical antifungal research has been cited for the dearth of preclinical candidates despite a global market worth in excess of US $6 billion 13 . Traditionally antifungal agents were discovered by screening large libraries of natural products or synthetic small molecules for their fungistatic and, preferably, fungicidal properties 14 . The polyenes and echinocandins were both derived from natural product screening. Unfortunately many subsequent screens 'rediscovered' the same basic chemical scaffolds 14 . The antifungal pipeline has displayed modest progression 15 , with only a single new antifungal class currently undergoing late-stage clinical trials (Phase IIb, NCT03583164, ClinicalTrials.gov). While the introduction of additional azoles such as isavuconazole 16, 17 provides greater options to reduce side effects and simplify dosing regimens, the development of resistance is not adequately addressed by new members of this widely used class 18 .
A major characteristic feature of fungi is the presence of a highly ordered carbohydrate cell wall that provides protection against chemical and mechanical stresses. The cell wall is a dynamic, interlaced and only partially defined polysaccharide structure that is essential for survival 19 and is considered an attractive source of novel antifungal targets due to its absence in humans. The A. fumigatus cell wall predominantly consists of a central core of fibrils composed of branched β-1,3 glucan cross-linked to chitin. Polysaccharides such as β-1,3-1,4-glucan and galactomannan are covalently bound to this complex while those contained in the surrounding cement include a-1-3 glucan. Cell wall biosynthesis and remodelling is a highly organised and complex process although many of the key steps remain to be fully elucidated 19 . Polysaccharide synthesis of β-1,3 glucan and chitin occur at the fungal cell membrane using intracellular sugar nucleotide donors as substrates. Chitin is an integral structural component of the cell wall in A. fumigatus contributing to rigidity and consists of a linear polymer of β(1-4)-linked N-acetyl-Dglucosamine (GlcNAc). Chitin synthesis remains an attractive drug target, however, targeting the entire chitin synthase family is not a viable option due to predicted differences in structure and the membrane bound location of the eight proteins 20 .
An alternative target to chitin synthases is biosynthesis of the sugar nucleotide substrate UDP-GlcNAc that is also utilised for the synthesis of GPI anchors and N-and O-linked glycans 21 .
Four highly conserved enzymes in UDP-GlcNAc biosynthesis form the hexosamine biosynthetic pathway 22 which is believed to represent the only endogenous source of UDP-GlcNAc within fungal cells 23 . Approximately 2-5% of glucose that enters the cell is directed into this pathway where it is phosphorylated to glucose-6-phosphate (Glc-6P) and subsequently converted to fructose-6-phosphate (Fruc-6P). Four enzymes catalyse the remaining steps of this pathway.
Glucosamine-6-phosphate synthase (Gfa1) converts Fruc-6P to glucosamine-6-phosphate (GlcN-6P). This undergoes acetylation by glucosamine-6-phosphate N-acetyltransferase (Gna1) to N-acetyl-glucosamine-6-phosphate (GlcNAc-6P). The next step involves isomerisation by phospho-acetyl-glucosamine mutase (Agm1) to yield N-acetyl-glucosamine-1-phosphate (GlcNAc-1P) before uridylation by N-acetyl-glucosamine-1P-uridyltransferase (Uap1) to produce UDP-GlcNAc. This pathway is highly regulated in filamentous fungi, yeast and higher eukaryotes 23 . Three of the enzymes (Gfa1, Agm1 and Uap1) have been genetically validated in A. fumigatus as essential for growth under in vitro laboratory conditions [24] [25] [26] .
Gna1 (EC 2.3.1.4) is a member of the Gcn5-related N-acetyltransferase (GNAT) superfamily and is present in yeast such as Candida spp. (e.g. Candida albicans, Candida glabrata and Candida auris) and Saccharomyces cerevisiae. Genetic studies in S. cerevisiae have demonstrated that deletion of GNA1 is lethal 27 . In C. albicans GNA1 is essential for in vitro viability and attenuated virulence in a murine model of disseminated candidiasis 28, 29 . Inactivation of the murine GNA1 homologue is lethal as it is implicated in mitotic membrane fusion events and this further reinforces a critical role for this enzyme in higher eukaryotes 30 . Though evolutionarily and 5 structurally distinct from higher eukaryotic organisms, the GNA1 orthologues recently identified in parasitic protozoan apicomplexans have been suggested as potential therapeutic targets 31 .
To date, Gna1 in A. fumigatus is unexplored as an antifungal drug target using a combination of genetic and chemical methods. Inhibitors that chemically phenocopy a GNA1 deletion have not been reported in any organism and the high degree of sequence homology between eukaryotic GNA1 family members likely preclude fungal selectivity. Here, we report a multidisciplinary approach providing genetic, chemical and structural evidence supporting A. fumigatus Gna1 as an antifungal target and describe a fragment that exploits a previously unidentified pocket selective for the fungal enzyme.
Results

Disruption of gna1 leads to a terminal phenotype that is rescued by exogenous GlcNAc
To investigate the requirement for Gna1 in A. fumigatus UDP-GlcNAc biosynthesis, we deleted GNA1 by homologous recombination. A Dgna1 strain was constructed by replacing the coding sequence with a pyrG selection marker ( Figure S1 ). Transformants were evaluated by phenotypic and PCR screening before verification by Southern Blot (Figure S1 ). Using a similar approach, GNA1 (with a N-terminal HIS tag) was re-introduced into the Dgna1 mutant ( Figure S1 ). Although suitable for initial in vitro studies, it was imperative that the reconstituted strain restored pyrG prototrophy as pyrG-A. fumigatus strains are highly attenuated in murine models of aspergillosis 32 . To address this, the pyrG-strain was targeted with random integration of A. fumigatus pyrG into the chromosome to generate a pyrG+ reconstituted strain ( Figure S1 ).
In vitro growth of A. fumigatus Dgna1 was completely inhibited in glucose (Glc) supplemented media and restored to comparable levels upon replacement of glucose with GlcNAc, the product of the Gna1 enzyme ( Fig. 1a ). This demonstrates that GNA1 is essential for viability of A. fumigatus in standard in vitro laboratory media rich in glucose and concurs with previous work in yeast 27, 29 . We considered the physiological relevance of these Glc and GlcNAc concentrations since failure to correlate with physiological nutritional availability may incorrectly assign a gene as essential for growth. The glucose concentration used is 20-fold greater than the mean physiological human blood glucose level (110 mM vs. ~5.5 mM) and in lung alveoli glucose concentrations are further reduced (~ 0.1 mM) 33 . Specific human physiological levels of GlcNAc are unspecified in the literature but regarded "low" and subject to fluctuation. We initially investigated rescue of Dgna1 on solid media supplemented with Glc (0.1 mM) and a simulated range of physiological GlcNAc concentrations, above and below previously reported levels 29 (Fig.   1a ). The Dgna1 growth phenotype in the presence of "low" GlcNAc levels (1.5 μM) was characterised by a complete loss of hyphae and melanin pigment. "High" GlcNAc levels (150 μM, 100-fold increase) partially restored hyphal development but colonies were still strikingly devoid of pigmentation and overall radial growth was less than the parental and reconstituted strain. We describe these characteristics as a terminal phenotype.
To dissect the interplay between exogenous Glc and GlcNAc, we developed a checkerboard assay to assess 285 different nutritional combinations of these to explore possible concentrations encountered by A. fumigatus in the human host and environment ( Fig. 1b ). Heatmap analysis demonstrated that loss of GNA1 is associated with a terminal phenotype defective in conidial pigmentation and hyphal growth across a range of estimated physiological concentrations. Taken together, these experiments show that disruption of gna1 leads to a terminal phenotype that is rescued by exogenous GlcNAc.
The Dgna1 strain displays a cell wall phenotype
Next, we investigated whether rescue of GNA1 with exogenous GlcNAc induces a cell wall stress response. A. fumigatus harbours cell wall integrity pathways that are activated under conditions of stress by signalling pathways such as the mitogen activated protein kinase (MAPK) cascades 34 . Due to the terminal phenotype not yielding sufficient growth for comparative analyses, this experiment was performed using a GlcNAc concentration of 90 mM to rescue growth. At concentrations of £ 10 4 viable conidia, the Dgna1 mutant displayed increased sensitivity to agents compromising the cell wall and membrane, suggesting the presence of cell wall defects and/or loss of membrane integrity ( Fig. 1a ). Calcofluor White (CW) interacts with chitin leading to disruption of chitin polymer assembly and impairing the corresponding linkages to other cell wall components 35 . Increased susceptibility to Congo Red (CR) suggests a reduction of β-1,3 and β-1,6 glucans. Increased sensitivity to Sodium Dodecyl Sulphate (SDS) reflects a compromised membrane that may be due to differences in the chitin layer. Finally, we investigated whether loss of A. fumigatus GNA1 enhanced the effects glucan synthesis inhibition by the echinocandin caspofungin ( Fig. 1a ). Exposure to caspofungin induced a terminal phenotype in the Dgna1 mutant (³ 10 4 conidia) and was fungicidal at lower concentrations. This provides evidence of synergistic in vitro activity of a beta glucan synthase inhibitor together with the Dgna1 mutant.
To probe the effects of Glc on germination, parental and Dgna1 mutant germlings were examined by light microscopy (Fig. 1c ). Under conditions tested the Dgna1 mutant was non-viable ( Fig. 1a ) and examination of the conidia demonstrated a subset that were enlarged and highly disorganised with evidence of multiple, rudimentary germ-tubes whose development was prematurely arrested (Fig. 1c ). Despite macroscopically comparable phenotypes, the Dgna1 mutant conidia incubated in the presence of 90 mM GlcNAc also displayed abnormalities compared to the parental strain ( Fig. 1c ). Although hyphae were evident at 24 h, there was also evidence of conidial enlargement and a lack of polarised hyphal growth with some Dgna1 germ tubes unable to branch ( Fig. 1c ). We hypothesise that this sub-population of abnormal conidia accounts for the significant reduction in viability of the A. fumigatus Dgna1 strain ( Fig. 1c ). GlcNAc is unable to completely rescue this phenotype. This suggests a possible cell wall phenotype due to reduced flux through the hexosamine biosynthetic pathway.
Defects in the cell surface architecture of the parental and Dgna1 mutant strains were also revealed by both Scanning Electron Microscopy (SEM) and Transmission Electron Microscopy (TEM). SEM analysis demonstrated that the Dgna1 mutant grown under terminal phenotype conditions (0.1 mM Glc and 1.5 μM GlcNAc) displayed conidiophore collapse (Fig. 1d ). The vesicular head was grossly abnormal with the presence of "naked" phialides and no obvious conidia compared to the parental strain ( Fig. 1d ). TEM analysis revealed a disorganised cell wall ultrastructure for the Dgna1 mutant, with a less defined chitin layer and a more dispersed outer mannoprotein layer (Fig. 1d ). These data suggest that loss of GNA1 is associated with a defective and potentially more porous cell wall and provides a molecular basis for the observed synergy with caspofungin. Taken together, these data show that the Dgna1 strain displays a cell wall phenotype.
GNA1 contributes to A. fumigatus virulence in models of aspergillosis
Ascertaining the physiological implications of GNA1 loss by translating in vitro phenotypic characterisations into in vivo infection models is an important step in providing genetic validation as an antifungal target. In particular, it is critical to determine whether in vivo GlcNAc scavenging systems could compensate for GNA1 loss. Non-vertebrate mini-host model systems such as the greater wax moth larvae (Galleria mellonella) represent a rapid initial screening strategy 36 . Larval inoculation resulted in a mean survival time of 3 days for the parental and reconstituted strains whereas the Dgna1 mutant was avirulent with a survival profile indistinguishable from the PBS control group ( Fig. 2a ).
A disadvantage of G. mellonella is that it fails to represent the natural inhalation route of Aspergillus. To recapitulate inhalational acquisition of A. fumigatus and provide insight into the physiological interplay of alveolar glucose and GlcNAc levels in circumventing GNA1 loss, we used an established neutropenic murine model of invasive pulmonary aspergillosis 37 . A preliminary study was performed using three concentrations of viable A. fumigatus conidia and the contribution of the Dgna1 mutant to pathogenicity was compared with the parental and reconstituted strains. In this experiment, the Dgna1 mutant was less virulent (Fig. 2b) . The median survival time was four days for the parental and reconstituted strains whereas a value could not be determined for the Dgna1 mutant (75% survival). This finding was confirmed in a subsequent study ( Fig. 2c ) using doses refined for each strain designed to induce signs of invasive aspergillosis after approximately 3 days post inhalation (see Supplemental Experimental Methods). Although the mean survival times between A. fumigatus strains are not directly comparable due to differences in dose, there was an 83% survival rate to day 10 for mice exposed to the lowest concentration (x0.25) of the Dgna1 mutant strain compared to 33% and 0% for the parental and reconstituted strains at their highest concentrations (x4.00, see Table S2 ). Approximately 1 to 2 log higher concentrations of Dgna1 were required to induce clinical disease ( Fig. 2c ). Overall these findings suggest that a degree of metabolic (GlcNAc) rescue of Dgna1 may occur in vivo. Nevertheless, these data show that GNA1 contributes to A. fumigatus virulence in models of aspergillosis.
Discovery of small molecules that target the Gna1 dimer interface
There are currently no selective small molecule inhibitors for the Gna1 class of enzymes to attempt to chemically phenocopy the genetic phenotype. Mechanistically, A. fumigatus (Af) Gna1
facilitates N-acetylation of GlcN-6P by promoting direct nucleophilic attack at the thioester carbonyl group of the acetyl co-enzyme A (AcCoA) cofactor by the sugar-phosphate amino group 38 . Although sharing only 30% sequence identity, structurally AfGna1 and Homo sapiens (Hs) Gna1 adopt the same overall fold and domain architecture, with highly conserved regions localised to the AcCoA binding site with minor differences in the sugar substrate binding region.
These differences are localised to amino acids involved in sugar-phosphate group recognition, which in the fungal enzyme utilise side chain functionality that is less polar in character 38, 39 . In an attempt to circumvent issues of high structural homology between human and fungal Gna1, we deployed a fragment-based approach 40 to discover small molecules that target previously unidentified pockets that are selective for the fungal enzyme. Bio-layer interferometry (BLI) was used to identify Gna1 binders from a 650 compound in-house fragment library [41] [42] [43] . This produced an initial hit rate of 5.7% ( Figure S2 ). The top hit (1, Fig. 3a ) displayed stoichiometric binding and high ligand efficiency (LE = 0.57 kcal mol -1 NHA -1 for 1), with a 6 μM equilibrium dissociation constant which was confirmed by isothermal titration calorimetry (ITC) ( Figure S2 ).
We next used X-ray crystallography to determine the binding mode of 1. AfGna1 was cocrystallised with AcCoA and soaked into solutions of 1. Synchrotron diffraction data to 1.6 Å ( Fig   3 , Table 1 ) were collected and used to solve the structure by molecular replacement. Previous work has shown that A. fumigatus Gna1 possesses a classic GNAT α/β fold, forming an obligate homodimer. This dimer shows extensive secondary structure swapping with substrate and cofactor binding to the two active sites that are formed by channels on the surface of the enzyme, composed of amino acids from both AfGna1 monomers 39 . Intriguingly, electron density corresponding to fragment hit 1 was observed in a pocket buried at the dimer interface in the core of the enzyme, binding across a crystallographic two-fold axis that generates the AfGna1 homodimer and the symmetry-related molecule of fragment hit 1, visible in the AfGna1-1 co-complex structure (Fig. 3b ). This hydrophobic pocket (~400 Å 3 ) accomodates fragment hit 1 which is positioned ~8 Å from both GlcN-6P substrate binding sites with a histidine residue (H127) from each monomer trapping the fragment in a p-p stacking arrangement ( Fig. 3b ). Critically, AfGna1
H127 is substituted with an arginine (R118) in the human enzyme, blocking the pocket and importantly, preventing fragment binding to HsGna1 (Fig. 3b , Figure S3 ), whereas H127 is conserved amongst clinically relevant fungal species ( Figure S3 ). With the exception of R118, the amino acids lining the fragment binding pocket are conserved between clinically relevant fungal Gna1 orthologues and HsGna1 ( Figure S3 ).
To develop the fragment scaffold towards AfGna1-selective inhibition, the binding characteristics of the fragment within the dimer interface pocket were explored to identify the structural requirements for optimal AfGna1 binding ( Figure S2 ). The staggered bi-ring system of 1 in the AfGna1-1 complex is likely a consequence of reducing steric repulsion between the orthochloro substituent of the aryl ring system and the adjacent 1,2,4-triazole (dihedral angle, θ; ~51°).
This results in optimal positioning of 1 to facilitate the important p-p stacking interactions with the H127 residues present in the pocket (Fig. 3b ). It appeared essential to maintain this bi-ring arrangement as loss or replacement of the ortho-substituent increased or ablated binding affinity ( Figure S2 ).
With the ortho-chloro substituted scaffold identified we considered the close proximity of the glutamic acid residue (E129) that separates fragment hit 1 and the substrate binding site from each respective AfGna1 monomer. Superposition of AfGna1-GlcNAc-6P complex (the Nacetylated enzymatic product of GlcN-6P; PDB 2VXK), onto the co-complex structure of AfGna1 with 1 illustrates the close proximity of the E129 side chains to the fragment hit 1 (3.4 Å) and to the substrate binding sites (8.2 Å) ( Fig. 3b ). Previous Gna1 studies have indicated that orthologous glutamate residues, whilst not playing a catalytic role, contribute to substrate and cofactor binding through direct contacts and through hydrogen-bond mediated water interactions 27, 44, 45 . Indeed, our data demonstrate that mutations which remove the E129 carboxylate (E129A) or substitute it with the corresponding amide (E129Q), reduced enzymatic activity compared to WT AfGna1 ( Figure S4 ). As such, we hypothesised that the close proximity of E129 residues to fragment hit 1 may offer scope to develop derivatives that exploit the E129 the side-chain functionality to both improve fragment binding affinity and elicit enzyme inhibition through perturbation of E129-mediated interactions ("E129 modulation approach", Fig. 3a ).
To explore the feasibility of harnessing E129-fragment proximity towards enzyme binding and inhibition, a meta-anilino group was installed into the scaffold. This resulted in fragment derivative 2, which displayed sub-micromolar affinity (0.8 μM, Fig. 3a ). Derivative 2 also displayed improved ligand efficiency compared to fragment hit 1 as a result of this minimal scaffold addition, resulting in a highly efficient binder (LE = 0.64 kcal mol -1 NHA -1 for 2). Overall, 2 maintains the important p-p binding interaction observed in the AfGna1-1 complex structure. As observed in the AfGna1-2 complex structure, the introduction of the meta-anilino group causes a positional shift of 2 (32 o from fragment hit 1), facilitating a hydrogen bond interaction between 2 and the E129 side chain that likely drives the observed enhancement in binding affinity ( Fig. 3 ). Although derivative 2 did not show inhibition against AfGna1 in a recombinant enzyme assay, exploiting the proximity of the E129 side chains may be a route to improving binding potency whilst providing an anchoring point from which to introduce chemical functionality to modulate the position or protonation state of the E129 residues in order to achieve inhibition.
As an alternative approach to achieving AfGna1 inhibition, we aimed to exploit the protein tunnels that connect the dimer interface fragment binding pocket to the substrate binding sites (distance of 1 to substrate binding site = ~8 Å, Fig. 3 ). Extension of the fragment scaffold into the active sites by traversing these tunnels would effectively generate a competitive enzyme inhibitor by blocking substrate binding at both AfGna1 active sites ("bifurcation approach", Fig. 3a ).
In contrast to E129 modulation, the success of bifurcation is predicated upon the ability of fragment hit 1 derivatives to both successfully reach the buried dimer interface binding pocket and be spatially accommodated despite the concomitant increase in fragment molecular size, which could conceivably hinder binding on both accounts. In order to test the ability of a bifurcated derivative of 1 to bind AfGna1, 3 was synthesised. This bifurcated fragment introduces an N,Ndiethyl alcohol moiety into the scaffold and displays a binding affinity of the same order as fragment hit 1 (5 μM, Fig.3a , Figure S2 ). Importantly, this illustrates that the introduction of a bifurcated modification into the fragment scaffold is tolerated and that fragment binding affinity is maintained and not compromised by the introduction of simple linker groups. An AfGna1-3 complex structure, which additionally contains Glc-6P, indicates that 3 is accessible to the fragment binding site, despite narrow tunnels linking the fragment binding pocket to the enzyme active sites (Fig.3b , Figure S3 ). Like fragment hit 1 and 2, the important binding interactions and binding mode are maintained in the AfGna1-3-(Glc-6P) complex structure. In addition, the hydroxy-functionality of the N,N-diethyl alcohol moiety displaces H127-coordinating water molecules and interacts with the acceptor nitrogen atoms of the H127 side chains (Fig. 3b ). The introduction of a para-anilino anchoring point for bifurcation leverages the sp 2 character of the anilino-nitrogen, maintaining the planarity necessary at the branch point for correct N,N-diethyl alcohol orientation whilst ortho-dichloro substitution positions the fragment along the 2-fold crystallographic axis (with a positional shift of 0.6 Å and 19 o reorientation from fragment hit 1). As a result, bifurcation vectors are identically orientated towards both AfGna1 active sites in contrast to the binding positions of fragment hit 1 and 2 (Fig. 3b) . Moreover, the positioning of the Glc-6P 12 6.2 Å from the ethyl chain linker of 3, visible in the AfGna1-3-(Glc-6P) complex structure ( Fig. 3b , Figure S3 ), is suggestive of fragment-linking approaches towards AfGna1 inhibition, albeit challenging due to the limited size of the tunnel 46 . In line with this, derivative 3 did not show inhibition against AfGna1 in a recombinant enzyme assay, probably due to the inability of the N,N-diethyl alcohol moiety to extend into and block the enzyme active sites.
Globally, the structural differences between the co-complexes of AfGna1 with 1, 2 and 3 are negligible (RMSD ~0.35 -0.40). However, when considering buried protein pockets and cavities in general, such seemingly trivial displacements may be of significance. Recent molecular dynamics simulations and experiments have suggested that large scale side chain or secondary structure conformational changes are not a pre-requisite for ligand binding to buried cavities but rather subtle and rapid movement of peptide structural elements can be sufficient to facilitate ligand ingress and egress [47] [48] [49] [50] . Although beyond the scope of this work, we speculate that the effects of any subtle movement of structural elements may propagate within AfGna1 and be important for ligand binding dynamics to the unusual buried dimer interface pocket. Taken together, we have discovered small molecules that target a fungal specific binding hotspot at the Gna1 dimer interface, providing a scaffold for the development of Gna1 inhibitors.
Discussion
The current clinical management of invasive fungal infections is multi-faceted and as a consequence of limited antifungal pipeline progression, clinicians must preserve the finite number of agents available to manage infection 51 . Recent decades witnessed an exodus of research and development into antifungal drug discovery by the pharmaceutical industry resulting in very few agents with novel mechanisms of action undergoing clinical trials. Clinical need prevails, despite optimal antifungal therapy, mortality rates remain around 50% although patient co-morbidities also contribute 1 . In response, a multidisciplinary approach to develop new targets has been advocated 52 .
Successful identification and validation of novel and ligandable targets is critical to the progression of the antifungal pipeline but the current shortage of unique targets combined with the intrinsic therapeutic hurdles introduced by the similarities of fungal and human enzymes only serves to complicate an already underappreciated and growing medical problem 1, 2, 53 . An attractive antifungal target is the cell wall, a structure unique to fungi and essential for survival.
The sugar polymers constituting the cell wall are all synthesised from sugar nucleotide precursors. Here, we used a multidisciplinary approach focused on an essential step in the biosynthesis of the sugar nucleotide, UDP-GlcNAc, the precursor of cell wall chitin as a target against A. fumigatus. Cell wall chitin has long been proposed as an antifungal target. The nikkomycins and polyoxins are substrate analogues of UDP-GlcNAc and inhibit chitin synthesis in vitro with a predilection for CHS-A but fail in vivo primarily due to resistance in chitin synthase isoenzymes [54] [55] [56] . Our approach circumvents this failure by targeting Gna1, a GNAT-family enzyme with no isoforms. Inhibitors targeting other GNAT family members are known in the literature 57, 58 , with bisubstrate inhibitors -molecules incorporating tethered mimics of both substrate and cofactor -offering improved selectivity profiles compared to alternative approaches but harbouring non-ideal pharmacokinetic properties [59] [60] [61] [62] [63] . However, such an approach is unlikely to offer robust selectivity in the case of Gna1 due to the high structural homology between fungal and human enzyme.
Previous failings in target-based drug discovery derive from an inadequate initial assessment of a molecular target in terms of physiological function 64 . Although GNA1 was shown to be essential for in vitro growth in S. cerevisiae and C. albicans 27, 29 , intrinsic differences in gene function across fungi due to diverging biological and physiological functions, genetic redundancies or scavenging pathways precludes predictions. Essentiality in yeasts does not automatically correlate in A. fumigatus and therefore this was experimentally validated to justify any potential investment in future inhibitor development. We demonstrated that genetic disruption of A. fumigatus GNA1 results in a terminal phenotype under simulated physiological Glc and GlcNAc concentrations. This is further supported by our in vivo study using a neutropenic murine model of invasive aspergillosis with inhalation of A. fumigatus Dgna1 approximately 100-fold less pathogenic than control strains. While the finding corroborates previous work (Mio et al., 2000) , we speculate that earlier in vitro studies were not sufficiently robust to detect physiologically relevant nutritional rescue strategies since if a gene were genuinely "essential" it would result in avirulence rather than attenuation. Gene deletion strategies incorporating nutritional rescue do not permit different levels of GNA1 expression to be directly investigated. Altering the levels of extracellular GlcNAc reflects the ability of A. fumigatus to induce salvage pathways.
Synergy between cell wall active agents is increasingly seen as an attractive option for antifungal treatment 65 . This is exemplified in vitro in A. fumigatus by the synergy between nikkomycin and the echinocandins 66 . At present the echinocandins are advocated as salvage therapy in invasive aspergillosis in part due to their fungistatic activity 67 . We show that A.
fumigatus Δgna1 combined with caspofungin has a fungicidal effect on in vitro growth completely abolishing not only the terminal phenotype but also growth under maximal GlcNAc rescue. This provides further evidence that combining a β-glucan synthase inhibitor together with chitin inhibition is synergistic in vitro. A GNA1 inhibitor could enhance the efficacy of the echinocandins and offer additional treatment modalities potentially as a resistance sparing agent. In terms of biological importance, Gna1 is an attractive antifungal target.
In addition to our genetic validation of Gna1, we sought to identify compounds that would chemically phenocopy the biological phenotype. The inherent difficulty in leveraging inhibitor potency and selectivity between high-homology enzyme families amongst higher eukaryotic organisms is a challenging problem to fully resolve. This applies to Gna1 where deletion in A. fumigatus yields a terminal phenotype, but deletion of the murine orthologue leads to developmental phenotypes 68 . We pursued a fragment-based approach to overcome this challenge by discovering a previously unidentified fungal selective pocket within AfGna1, positioned on the two-fold axis generating the Gna1 biological homodimer. Crucially, this pocket is absent in the human orthologue, where it is occupied by larger side chains (arginines, versus histidines in the fungal enzyme).
Our data show that fragment derivatives can recapitulate binding to this unusual fragment anchoring site and rational design targeting this pocket allows the development of micromolar binders that do not target the human enzyme. Although not yet displaying AfGna1 inhibitory activity at high micromolar concentrations, the opportunities towards fungal-selective AfGna1 inhibition opened up by the discovery of fragments binding at this fungal-selective binding pocket is promising. Moreover, with the exception of R118, the amino acids that constitute the interface binding pocket are well conserved between clinically relevant fungal Gna1 orthologues and HsGna1. Although sequence alignments have limited predictive capacity in determining the structural context of the interface pocket and its ligandability, this high degree of conservation warrants further structural and chemical exploration. This binding pocket may offer a ligandable handle against other fungal Gna1 orthologues, in particular, C. auris which recently became the first fungal species listed as an urgent drug resistant threat 11 .
Identifying and pursuing novel avenues for inhibitor development to overcome organism selectivity barriers is critical to reversing the dearth in the antifungal pipeline as is the timely identification and validation of unusual and novel targets, exemplified herein by Gna1.
The work reported here also serves to further exemplify the ability of fragment-based screening to uncover unique and otherwise unforeseen avenues towards enzyme inhibition through the discovery of novel binding sites. Successful fragment campaigns that provide the foundation to potent inhibitors commonly begin with fragments that display no intrinsic enzymatic inhibitory activity 69 . The fact that fragment hit 1 and derivatives (2 and 3) display a stable binding mode is often an important pre-requisite to subsequent successful fragment development campaigns 70 .
Moreover, while small molecule therapeutics that bind to protein interfaces are uncommon, such approaches have been successfully utilised in structure-based design campaigns to inhibit enzyme targets. For example, HIV-1 and HIV-2 protease inhibitors, such as Darunavir, bind to a cavity at the protein dimer interface located adjacent to the enzyme active site, forming contacts to the interface cavity and inhibiting enzymatic activity through hydrogen-bonding to catalytically important D25 carboxylate side-chains of both protease monomers thereby competitively inhibiting viral polypeptide access [71] [72] [73] .
The AfGna1-3-(Glc-6P) complex structure offers a glimpse at potential avenues of inhibition via a combination of bifurcation and fragment-linking approaches. Although a rare and challenging form of fragment development, successful fragment-linking campaigns ideally utilise the conjugation of fragment pairs with contrasting hydrophobic and polar ligand-protein binding characteristics 46 . Such characteristics are exemplified herein with fragment hit 1 and the sugar (or pseudo-sugar) substrate and therefore provide an incentive to further explore this approach.
In parallel, exploring potential routes towards E129 modulation of substrate binding has led to the synthesis of a sub-micromolar fragment binder and a key chemical scaffold which can now be further explored and modified to elicit the desired inhibitory response.
In summary, we have provided genetic validation of AfGna1 as an antifungal target and have discovered small molecules that target the Gna1 dimer interface, providing a platform for generating inhibitors of the enzyme. As demonstrated, our multidisciplinary approach, 
Materials and methods
Ethics statement
All animal experiments were performed by Evotec Ltd (UK) under UK Home Office Licence 40/3644 and ethically approved by The University of Manchester Standing Committee.
Strains, culture medium and solutions
The genetic lineage and nutritional growth requirements of all strains used and generated in this work is provided in Table S1 . Further details are provided in the Supplemental Experimental Methods.
Generation of A. fumigatus Δgna1 mutant
To delete GNA1, construct pDgna1pyrG+ was designed to replace the entire 644 bp coding region of GNA1 with the URA-blaster (also called the pyrG blaster) as a reusable selection marker by homologous recombination 74 (Figure S1 ). Refer to the Supplemental Experimental Methods for all PCR primer sequences used in this work. The Supplemental Experimental Methods contain details of the experimental process including protoplast transformation, phenotypic screening, PCR screening and Southern Blot verification ( Figure S1 ) of A. fumigatus Δgna1.
Generation of an A. fumigatus GNA1+6H::pyrG+ reconstituted strain
A construct pGNA1+6H was designed to replace the entire URA-blaster (8.3 kb) in the Δgna1 mutant with the native GNA1 sequence by homologous recombination (Figure S1 ).
Experimental procedures culminating in Southern Blot verification followed those for generation of the Δgna1 mutant (see Table S1 and Supplemental Experimental Methods). To permit in vivo applications by restoring uridine and uracil autotrophy, the reconstituted strain (GNA1+6H::pyrG-) was complemented with pyrG by random integration. Primers were used to amplify a 1.9 kb portion of the A. fumigatus pyrG gene 75 from pXDRFP4 76 
. Refer to Supplemental Experimental
Methods for further details.
In vitro phenotypic analysis of A. fumigatus Δgna1 mutant
An agar dilution method was used to investigate in vitro growth in the presence of different To examine the response of the A. fumigatus Δgna1 mutant to cell wall perturbing agents, suspensions of conidiophores (5 μl, 1 x 10 6 -1 x 10 2 ) were inoculated onto solid 0.1 mM Glc CM + ³ 50 mM GlcNAc in the presence of Calcofluor White, Congo Red, Sodium Dodecyl Sulphate (SDS) (25 -100 μg/ml) and Caspofungin (0.0625 -0.5 μg/ml). Following incubation (48 h), plates were examined. The experiment was performed three times.
For analysis of cell wall architecture, conidia and mycelia were grown on solid medium, fixed, processed and examined using transmission and scanning electron microscopy. Refer to Supplemental Experimental Methods for further details.
A. fumigatus Δgna1 infection models
Greater wax moth larvae, Galleria mellonella, (Livefoods Direct, Sheffield, UK) were used as an infection model 36, 78, 79 . Larvae were maintained at room temperature in wood shavings in the dark 80 and those in the 6 th instar measuring 2.0 cm in length (approximately 250 mg) were randomly assigned into groups. The A. fumigatus parental, Δgna1 and reconstituted strains were inoculated into the hind proleg of larvae (n = 30 per group) as a 10 μl PBS suspension of 5 x 10 5 resting conidia. Negative controls were inoculated with PBS only. Larvae were protected from light, incubated at 37 °C and examined at 24 h intervals. Mortality, defined by lack of movement in response to stimuli and discolouration (melanisation) of the cuticle, was scored for 6 days.
An inhalational neutropenic murine model of invasive aspergillosis 37,81 was performed by Evotec Ltd (UK) (see ethics statement). As this was an initial proof of concept study and due to insufficient published literature using the parental strain in this particular murine model, group size by power analyses were unable to be performed for statistical differences between strains.
Sharing the data generated in this study will inform future power calculations.
Male CD1 mice (Charles River, UK) weighing 23-26 g were used for all experiments and allowed to acclimatise for at least 7 days. Mice were randomly assigned to groups and housed in sterilised individually ventilated cages with HEPA filtered sterile air and sterile aspen chip bedding (changed every 3-4 days). Food and water were provided ad libitum. The room temperature was 22 °C (±1 °C) with a relative humidity of 60% and maximum background noise of 56 dB. Mice were exposed to 12 h light/dark cycles.
Mice were rendered neutropenic with intraperitoneal cyclophosphamide (250 mg/kg on day -2 relative to infection, and 200 mg/kg on day +3) and sub-cutaneous cortisone acetate (200 mg/kg on day -2 and day +3). To generate conidial suspensions of the target inoculum (Table S2) with nutritional requirements as per Table S1 . Viable cell counts were performed on serially diluted aliquots of each conidial suspension.
Each cage was randomly assigned to a study group and infected by an inhalation chamber system 37 . On the day of infection, mice (n = 4 per group for experiment 1; n = 6 per group for experiment 2) were exposed for 1 h to 12 ml of PBS containing A. fumigatus conidia aerosolised via a Micro Mist® nebuliser (Teleflex Medical, Kernen, Germany) in an acrylic chamber.
Enrofloxacin (50 ppm, 0.2 ml/water bag) was administered from day -3 to day +10 to prevent bacterial infection. Mice were weighed and monitored at least daily and the study refined using surrogate markers for invasive pulmonary aspergillosis. Any mouse with signs of illness and distress* were culled immediately (terminal anaesthesia or cervical dislocation) and death recorded as being the next day. * A scoring system was used based on the following parameters: weight loss; hypothermia less than 32 °C; appearance (hunching, poor coat condition); clinical signs: respiration (noisy laboured breathing); tremors/convulsions; unprovoked behaviour (little peer interaction) and provoked behaviour (subdued when stimulated).
Statistical Analyses
Biological experiments were performed at least three independent times with the exception of electron microscopy. Statistical analyses were carried out using GraphPad Prism (v5.0b). Data is expressed as the mean ± SD (Fig. 1c) . To compare more than two groups, one-way ANOVA test with Bonferroni's multiple comparison test was used (Fig 1c) . For comparison of survival curves, the Kaplan-Meier Log-rank (Mantel-Cox) test was performed ( Fig. 2a only) .
AfGna1 protein expression and purification
AfGna1 was purified as described earlier 39 . Briefly, the sequence encoding the protein was inserted into a pGEX6P-1 vector for expression of a GST tagged fusion that contains PreScission protease cleavage site. For protein expression, the plasmid was transformed into Escherichia coli BL21(DE3) pLysS. Cell cultures were grown to an OD600 of 0.8 and expression was initiated by the addition of 250 µM IPTG at 17 °C. The cultures were then allowed to grow for a further 16 h before harvesting by centrifugation. After lysis, affinity chromatography and GST tag cleavage, eluted protein was concentrated and further purified by size exclusion chromatography using a Superdex 75, 26/60 column. Corresponding fractions confirmed by SDS-PAGE were pooled concentrated, flash frozen in liquid nitrogen and stored at -80 °C.
AfGna1 fragment screen and binding affinity measurements
To identify a potential fragment binder of AfGna1, the fragment library of the University of Dundee Drug Discovery Unit (DDU) comprising of 652 structurally diverse compounds was screened using biolayer interferometry (BLI) [41] [42] [43] . BLI experiments were performed on an Octet Red 384 system (Forte Bio, USA) using super streptavidin (SSA) biosensors and biotinyated-AfGna1
Primary hits identified from initial screening were defined as fragments with a response rate greater than three robust standard deviation units above the median. Confirmation of fragment hit binding was performed with a follow-up concentration dose-response series. Binding isotherms were fitted and visualised using Octet software (Forte Bio, USA) to derive dissociation constants (Kd). Refer to supporting information for further experimental details.
AfGna1 crystallography
AfGna1 crystallization was carried out as described earlier 39 with a combined total of 120 larvae per group). P < 0.0001.
b Neutropenic male CD1 mice were exposed to 1 x 10 7 A. fumigatus aerosolised conidia from the parental, Dgna1 mutant and reconstituted strains in an inhalational chamber (n = 4 per group).
c Neutropenic male CD1 mice were exposed to a trio of refined doses of A. fumigatus aerosolised conidia from the parental, Dgna1 mutant and reconstituted strains in an inhalational chamber (n = 6 per group). A reference dose of x 1.00 was set to that observed to induce signs of disease from day 3. Each symbol represents an individual animal. In b and c mice were monitored for up to 10 days post infection and any mouse showing clinical signs of disease or distress was culled immediately and death being recorded as the next day. Δgna1 (10 7 ) Reconstituted (10 7 ) Days post-infection Inocula concentration (cfu mL -1 ) 10 5 
apo-HsGna1
AfGna1-2 AfGna1-3 molecules of fragment hit 1, 2 and 3 are shown as transparent sticks. In apo-HsGna1, the novel dimer interface binding pocket is occluded by R118 residues preventing ligand binding. In AfGna1, substitution of R118 by H127 facilitates p-p stacking with 1, 2 and 3 forming the basis of fungal selective fragment binding. Superposition of enzymatic product, GlcNAc-6P (PDB 2VXK) onto co-complex structures AfGna1-1 and AfGna1-2 demonstrates the proximity of the fragment hit and derivatives to the E129 side chains and substrate binding sites. The AcCoA cofactor is not visible from selected viewpoint. The Fo−Fc map for the bound small molecules (fragment hit 1, 2 and 3) are shown as a mesh (grey) contoured to 2.5 σ. Statistics for the highest-resolution shell are shown in parentheses.
